{
    "clinical_study": {
        "@rank": "166297", 
        "arm_group": [
            {
                "arm_group_label": "BI 144807", 
                "arm_group_type": "Experimental", 
                "description": "Subjects receive multiple BID doses of BI 144807 solution"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects receive multiple BID doses of Placebo solution"
            }
        ], 
        "brief_summary": {
            "textblock": "In this trial the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of\n      multiple dose administration of BI 144807 will be investigated in otherwise healthy,\n      controlled asthmatic patients"
        }, 
        "brief_title": "Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy", 
            "Asthma"
        ], 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        1. mild asthmatic, otherwise healthy subjects (male and female of non-childbearing\n        potential)\n\n        Exclusion criteria:\n\n        1. Apart from mild asthma any relevant deviation from healthy conditions"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651598", 
            "org_study_id": "1313.2", 
            "secondary_id": "2012-001615-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "multiple dose (bid)", 
                "intervention_name": "Placebo to BI 144807", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "BI 144807", 
                "description": "multiple dose (bid, low to high dose)", 
                "intervention_name": "BI 144807", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom"
                }, 
                "name": "1313.2.44001 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Multiple Rising Doses of BI 144807 Powder for Oral Drinking Solution Over a Period of 14 Days in Otherwise Healthy Controlled Asthmatic Subjects in a Randomised, Double-blind, Placebo-controlled Trial", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number (% patients) of drug-related adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum measured concentration of the analyte in plasma after first dose (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours after first dose"
            }, 
            {
                "measure": "Maximum measured concentration of the analyte in plasma after last dose (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }, 
            {
                "measure": "Time from first dosing to maximum measured concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours after first dose"
            }, 
            {
                "measure": "Time from last dosing to maximum measured concentration (Tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }, 
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma over the time interval from t1 to t2 after administration of the first dose (AUCt1-t2)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours after first dose"
            }, 
            {
                "measure": "Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t (AUCt,ss)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }, 
            {
                "measure": "Terminal half-life of the analyte in plasma after the first dose (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "up to 24 hours after first dose"
            }, 
            {
                "measure": "Terminal half-life of the analyte in plasma at steady state (t1/2,ss)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }, 
            {
                "measure": "RA,Cmax (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval \u03c4, expressed as ratio of Cmax at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }, 
            {
                "measure": "RA,AUC (Accumulation ratio of the analyte in plasma at steady state after multiple oral administration over a uniform dosing interval \u03c4, expressed as ratio of AUC at steady state and after single dose)", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours after last dose"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}